Cytotoxicity and antiangiogenic activity of grandisin


Autoria(s): VALADARES, Marize C.; CARVALHO, Isabel Crhistyna Teles de; OLIVEIRA JUNIOR, Luiz de; VIEIRA, Marcelo de Sousa; BENFICA, Polyana Lopes; CARVALHO, Flvio Silva de; ANDRADE, Lorenna Vieira Silva; LIMA, Eliana Martins; KATO, Massuo Jorge
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

20/10/2012

20/10/2012

2009

Resumo

Objectives The antitumoural properties of grandisin, a tetrahydrofuran neolignan from Piper solmsianum, were investigated by in-vitro and in-vivo assays using the Ehrlich ascites tumoural (EAT) model. Methods Viability of the tumour cells was evaluated by Trypan blue exclusion and MTT methods, after incubation with grandisin (0.017-2.3 mu M). The effects of grandisin on the activity of caspase-3, -6, -8, and -9 were also investigated using colorimetric protease kits. In-vivo studies were performed in EAT-bearing mice treated intraperitoneally with 2.5, 5 or 10 mg/kg grandisin for 10 days. Key findings Grandisin inhibited the growth of EAT cells, by both methods, with IC50 values less than 0.25 mu M. The results showed that the activity of all the caspases studied increased in grandisin-treated cells, when compared with control, non-treated cells. Administering grandisin to EAT-bearing mice increased survival of the animals, in a dose-dependent manner. Simultaneously, we detected a 66.35% reduction of intraperitoneal tumour cell burden in the animals treated with 10 mg/kg grandisin. Additionally, in these animals, the marked increase of vascular endothelial growth factor (VEGF) levels, induced by EAT development, was decreased with treatment with grandisin, resulting in a reduction of 32.1% of VEGF levels in the peritoneal washing supernatant, when compared with the control. Conclusions The results demonstrated that grandisin induced in-vitro cytotoxicity and antiangiogenic effects in mice while it acted against tumour evolution, prolonging host survival.

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)

Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)

Financiadora de Estudos e Projetos (FINEP)

Financiadora de Estudos e Pesquisas (FINEP)

Fundacao de Amparo a Pesquisa da Universidade Federal de Goias (FUNAPE)

Fundacao de Amparo a Pesquisa da Universidade Federal de Goias (FUNAPE)

Identificador

JOURNAL OF PHARMACY AND PHARMACOLOGY, v.61, n.12, p.1709-1714, 2009

0022-3573

http://producao.usp.br/handle/BDPI/31127

10.1211/jpp/61.12.0017

http://dx.doi.org/10.1211/jpp/61.12.0017

Idioma(s)

eng

Publicador

WILEY-BLACKWELL PUBLISHING, INC

Relação

Journal of Pharmacy and Pharmacology

Direitos

restrictedAccess

Copyright WILEY-BLACKWELL PUBLISHING, INC

Palavras-Chave #antitumour #cytotoxicity #grandisin #vascular endothelial growth factor #EHRLICH ASCITES TUMOR #ANTITUMOR-ACTIVITY #INDUCED APOPTOSIS #GROWTH #ACTIVATION #INHIBITORS #CASPASE-8 #RECEPTOR #CANCER #Pharmacology & Pharmacy
Tipo

article

original article

publishedVersion